JWCTF (JW (Cayman) Therapeutics Co) Other Current Payables: $6.48 Mil (As of Dec. 2025)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
28 GF Score
Price $0.21
GF Value $0.58
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Other Current Payables?

JW (Cayman) Therapeutics Co JWCTF -9.27% 28 Other Current Payables is $6.48 Mil as of Dec. 2025. GuruFocus rates JWCTF with a GF Score™ of 28/100 and a GF Value™ of $0.58 (Possible Value Trap). The stock has 3 warning signs investors should review.

JW (Cayman) Therapeutics Co's Other Current Payables for the quarter that ended in Dec. 2025 was $6.48 Mil.

JW (Cayman) Therapeutics Co's quarterly Other Current Payables declined from Dec. 2024 ($6.15 Mil) to Jun. 2025 ($5.37 Mil) but then increased from Jun. 2025 ($5.37 Mil) to Dec. 2025 ($6.48 Mil).

JW (Cayman) Therapeutics Co's annual Other Current Payables declined from Dec. 2023 ($10.69 Mil) to Dec. 2024 ($6.15 Mil) but then increased from Dec. 2024 ($6.15 Mil) to Dec. 2025 ($6.48 Mil).

JW (Cayman) Therapeutics Co Other Current Payables Related Terms

JW (Cayman) Therapeutics Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for JW (Cayman) Therapeutics Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Other Current Payables Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 19.93 16.18 10.69 6.15 6.48

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.69 7.05 6.15 5.37 6.48
JWCTF
28GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JW (Cayman) Therapeutics Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $6.48 Mil mean?
JW (Cayman) Therapeutics Co (JWCTF) has a Other Current Payables of $6.48 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on JW (Cayman) Therapeutics Co and its competitors.
Is JW (Cayman) Therapeutics Co's Other Current Payables too high?
JW (Cayman) Therapeutics Co's current Other Current Payables is $6.48 Mil. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Other Current Payables compare to VRTX and REGN?
JW (Cayman) Therapeutics Co's Other Current Payables of $6.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on JW (Cayman) Therapeutics Co and its competitors. JW (Cayman) Therapeutics Co's current Other Current Payables is $6.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.58, compared to a current price of $0.21 — trading 63.5% below its estimated fair value. The current Other Current Payables is $6.48 Mil. JW (Cayman) Therapeutics Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Other Current Payables is $6.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.21 is trading 63.5% below its estimated GF Value™ of $0.58. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • Other Current Payables: $6.48 Mil
  • GF Value™: $0.58 vs. price of $0.21 (63.5% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
28GF Score

Get the complete analysis for JWCTF

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price
$0.58
GF Value